Search clinical trials for: Camrelizumab ＋Immunotherapy

Total 969 results

Peking Union Medical College Hospital

Recruiting

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Radioactive Iodine-refractory Differentiated Thyroid Cancer

China
Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Beijing Friendship Hospital

Unknown

Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

Gastric Cancer

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-small-cell Lung Cancer

China
Guangdong Association of Clinical Trials

Not yet recruiting

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Non-Small-Cell Lung Cancer
Sun Yat-sen University

Recruiting

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Esophageal Squamous Cell Carcinoma

China
University of Manitoba
AstraZeneca; Manitoba Medical Service Foundation; CancerCare Manitoba

Recruiting

Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer (OPERARADIO)

Esophageal Cancer

Canada
Capital Medical University

Completed

Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer

Esophageal Carcinoma

China
Capital Medical University

Terminated

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Cancer | Mesothelioma, Malignant

China
Weill Medical College of Cornell University

Terminated

Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M)

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center

Terminated

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
ALK-Abelló A/S

Completed

House Dust Mite Allergy Trial In Children (MATIC)

Allergic Rhinitis Due to Dermatophagoides Farinae | Allergic Rhinitis Due to Dermatophagoides Pteronyssinus | Allergic Rhinitis Due to House Dust Mite

Spain, Russian Federation, United States, Poland, Bulgaria, Canada, France, Germany, Lithuania, Slovakia, Ukraine
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

CX3CR1+T Cell Predict Immunotherapy Efficacy

Non-small Cell Lung Cancer

China
Gradalis, Inc.

Temporarily not available

Expanded Access of Vigil in Solid Tumors

Cervical Cancer | Ovarian Cancer | Solid Tumor | Ewing Sarcoma | Uterine Cancer | Ewing's Tumor Metastatic | Ewing's Sarcoma Metastatic | Advanced Gynecological Cancers

United States
Novartis Pharmaceuticals
National Institute on Aging (NIA); Amgen; Banner Alzheimer's Institute

Terminated

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1)

Alzheimers Disease

United States, Belgium, United Kingdom, Germany, Australia, Canada, Spain, Finland, Switzerland, Netherlands
The First People's Hospital of Changzhou

Active, not recruiting

Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer

Breast Cancer
Children's Hospital of Philadelphia

Completed

Milk Oral Immunotherapy in Children to Treat Food Allergy

Milk Hypersensitivity

United States
Beijing Chest Hospital

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Non-small Cell Lung Cancer
Wen Tianfu

Recruiting

Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)

Advanced Hepatocellular Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Malignant Pleural Effusion
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)

Breast Cancer

China
Beijing Sanbo Brain Hospital

Suspended

Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)

Recurrent Glioblastoma

China
National Taiwan University Hospital

Completed

The Effectiveness of "Multi-Immunotherapy Special Training Courses Through Digital Media and Workshop" Intervention for Oncology Nurses: Exploration of Educational Needs, Curriculum Planning, Implementation and Evaluation

Education | Oncology | Immune

Taiwan
Stallergenes Greer

Completed

Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

Allergy

France
Fudan University

Not yet recruiting

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer (PTCA199-8)

Pancreatic Cancer
Di Wu

Recruiting

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

Melanoma

China
Zhejiang University

Recruiting

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Colon Cancer | Neoadjuvant Therapy

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
RenJi Hospital

Unknown

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Gastric Cancer Stage III

China
University of Milano Bicocca
Azienda Ospedaliera San Gerardo di Monza

Recruiting

Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC (I-STOP)

Non-small Cell Lung Cancer

Italy
University Hospital Inselspital, Berne
AstraZeneca

Terminated

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin (NITIMIB)

Muscle-invasive Bladder Cancer

Switzerland
Peking University People's Hospital

Not yet recruiting

Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma (NICLA)

Adenocarcinoma of Esophagogastric Junction

China
University Hospital, Ghent
University Ghent; Kom Op Tegen Kanker

Active, not recruiting

MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer (MIDRIX4-LUNG)

Non-small Cell Lung Cancer Metastatic

Belgium
Massachusetts General Hospital

Completed

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

Melanoma | Glioblastoma | Intracranial Tumors

United States
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients (CHANCE)

Oral Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Locally Advanced Cervical Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Fujian Medical University

Active, not recruiting

The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Locally Advanced Gastric Cancer

China
Ruijin Hospital

Active, not recruiting

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC (InTRist)

Local Advanced Non-small Cell Lung Cancer

China
CNAO National Center of Oncological Hadrontherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Fondazione IRCCS... and other collaborators

Recruiting

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC)

Melanoma | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma

Italy, Germany
Taipei Medical University WanFang Hospital

Completed

Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy (RFA)

Liver Cancer

Taiwan
Hebei Medical University

Not yet recruiting

Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Soft Tissue Sarcoma | Uterine Cancer | Advanced Non Small Cell Lung Cancer

China
Yongyi Zeng

Not yet recruiting

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Hepatocellular Carcinoma
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Cervical Cancer | Fertility Preservation | Neoadjuvant Chemoimmunotherapy

China
Fujian Cancer Hospital

Recruiting

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Digestive System Neoplasms | Esophageal Neoplasms | Esophageal Diseases

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Lung Cancer Stage II
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen...

Recruiting

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

Lung Cancer, Non-small Cell | Artificial Intelligence

China

Search clinical trials for: Camrelizumab ＋Immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations